Tetanus Toxoids Loaded Glucomannosylated Chitosan Based Nanohoming Vaccine Adjuvant with Improved Oral Stability and Immunostimulatory Response

被引:30
作者
Harde, Harshad [1 ]
Agrawal, Ashish Kumar [1 ]
Jain, Sanyog [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut, Ctr Pharmaceut Nanotechnol, Sas Nagar 160062, Punjab, India
关键词
chitosan nanoparticles; glucomannosylation; mucosal immunity; stability; vaccine; HIGHLY-VARIABLE DRUGS; SCALED AVERAGE BIOEQUIVALENCE; SIDED TESTS PROCEDURE; INDIVIDUAL BIOEQUIVALENCE; PRODUCTS; LIMITS; POWER; EMA;
D O I
10.1007/s11095-014-1449-5
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
The present report embarks on rational designing of stable and functionalized chitosan nanoparticles for oral mucosal immunization. Stable glucomannosylated sCh-GM-NPs were prepared by tandem cross linking method followed by lyophilization. The in vitro stability of antigen and formulation, cellular uptake and immunostimulatory response were assessed by suitable experimental protocol. Stability testing ensured the chemical and conformation permanency of encapsulated TT as well as robustness of sCh-GM-NPs in simulated biological media. The antigen release from sCh-GM-NPs followed initial burst followed by controlled Weibull's type of release profile. The higher intracellular uptake of sCh-GM-NPs in Raw 264.7 and Caco-2 was concentration and time dependent which mainly attributed to Clathrin and receptor mediated endocytosis via mannose and glucose receptor. The in vivo evaluation in animals revealed that sCh-GM-NPs posed significantly (p < 0.001) higher humoral, mucosal and cellular immune response than other counterparts. More importantly, commercial TT vaccine administered through oral or intramuscular route was unable to elicit all type of immune response. The sCh-GM-NPs could be considered as promising vaccine adjuvant for oral tetanus immunization. Additionally, this technology expected to benefit the design and development of stable peroral formulation for administration of protein, peptides and variety of other antigens.
引用
收藏
页码:122 / 143
页数:22
相关论文
共 27 条
[1]
[Anonymous], 2001, GUID NOT APPL CONS D
[2]
[Anonymous], 2010, CPMPEWPQWP140198REV1
[3]
[Anonymous], 2002, CPMPEWPQWP140198
[4]
Individual bioequivalence revisited [J].
Chen, ML ;
Lesko, LJ .
CLINICAL PHARMACOKINETICS, 2001, 40 (10) :701-706
[5]
Chow SC, 2004, DESIGN ANAL CLIN TRI, P483
[6]
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration [J].
Davit, Barbara M. ;
Chen, Mei-Ling ;
Conner, Dale P. ;
Haidar, Sam H. ;
Kim, Stephanie ;
Lee, Christina H. ;
Lionberger, Robert A. ;
Makhlouf, Fairouz T. ;
Nwakama, Patrick E. ;
Patel, Devvrat T. ;
Schuirmann, Donald J. ;
Yu, Lawrence X. .
AAPS JOURNAL, 2012, 14 (04) :915-924
[7]
Regulatory Conditions for the Determination of Bioequivalence of Highly Variable Drugs [J].
Endrenyi, Laszlo ;
Tothfalusi, Laszlo .
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2009, 12 (01) :138-149
[8]
Graphpad Software Inc, GRAPHPAD PRISM VERS
[9]
Evaluation of a scaling approach for the bioequivalence of highly variable drugs [J].
Haidar S.H. ;
Makhlouf F. ;
Schuirmann D.J. ;
Hyslop T. ;
Davit B. ;
Conner D. ;
Yu L.X. .
The AAPS Journal, 2008, 10 (3) :450-454
[10]
Bioequivalence approaches for highly variable drugs and drug products [J].
Haidar, Sam H. ;
Davit, Barbara ;
Chen, Mei-Ling ;
Conner, Dale ;
Lee, LaiMing ;
Li, Qian H. ;
Lionberger, Robert ;
Makhlouf, Fairouz ;
Patel, Devvrat ;
Schuirmann, Donald J. ;
Yu, Lawrence X. .
PHARMACEUTICAL RESEARCH, 2008, 25 (01) :237-241